By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Berg 

500 Old Connecticut Path
Bldg. B
Framingham  Massachusetts  01701  U.S.A.
Phone: 617-588-0083 Fax: n/a


SEARCH JOBS

Berg, is a biopharmaceutical company with a research focused on understanding how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of early-
stage technologies in CNS diseases and metabolic diseases that complement its late-stage
clinical trial activity in cancer and prevention of chemotoxicity. Armed with the use of the Berg Interrogative Biology™ discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow.

Berg's application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The Berg Interrogative Biology™ platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.

For additional information, please visit www.berghealth.com.


Key Statistics


Email: Info@Berghealth.com
Ownership: Private

Web Site: Berg
Employees:
Symbol: 
 









Company News
ASCO2016: Berg Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting 6/6/2016 12:06:32 PM
Berg Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer 4/27/2016 8:28:31 AM
Berg Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting 4/18/2016 10:20:39 AM
Berg Appoints Michael A. Kiebish As Chief Precision Medicine Officer 2/23/2016 7:46:50 AM
Berg Appoints Narain To Chief Executive Officer; Haddock Joins As Chief Financial Officer/ Chief Operating Officer 2/9/2016 7:17:06 AM
Berg Joins U.K. Prime Minister's Initiative, Genomics England To Sequence 100,000 Genomes 9/30/2015 10:00:30 AM
NIH To Evaluate Berg's Drug For The Treatment Of Kidney Cancer 9/8/2015 10:31:49 AM
Berg Partnership With University of Miami To Tackle Heart Disease 8/21/2015 8:00:06 AM
Berg Partnership With University of Miami To Tackle Heart Disease 8/19/2015 10:37:54 AM
ASCO15 EXCLUSIVE: Berg’s Lead Cancer Drug May Shift Cancer Metabolism, Says CEO 6/3/2015 8:54:11 AM
12
//-->